1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. California >
  6. Mirum Acquires Bluejay Therapeutics

M&A Deal Summary

Mirum Acquires Bluejay Therapeutics

On December 8, 2025, Mirum acquired life science company Bluejay Therapeutics for 620M USD

Acquisition Highlights
  • This is Mirum’s 2nd transaction in the Life Science sector.
  • This is Mirum’s largest (disclosed) transaction.
  • This is Mirum’s 2nd transaction in the United States.
  • This is Mirum’s 2nd transaction in California.

M&A Deal Summary
Date 2025-12-08
Target Bluejay Therapeutics
Sector Life Science
Buyer(s) Mirum
Deal Type Add-on Acquisition
Deal Value 620M USD
Advisor(s) Centerview Partners
J.P. Morgan Securities (Financial)
Latham & Watkins (Legal)

Target

Bluejay Therapeutics

Redwood City, California, United States
Bluejay Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing potentially life-changing therapeutics for serious viral and liver diseases. The company is currently investigating brelovitug for the treatment of chronic hepatitis delta virus (HDV) and chronic hepatitis B (CHB) viral infections. Additionally, Bluejay is advancing several innovative programs with the goal of developing a combination regimen to achieve a functional cure for chronic hepatitis B, including a proprietary TLR9 agonist (cavrotolimod) and a liver-targeted HBV transcript inhibitor (BJT-628). Bluejay Therapeutics is based in Redwood City, California.

Search 214,503 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Mirum

Foster City, California, United States
Category Company
Founded 2018
Sector Life Science
Employees334
Revenue 337M USD (2024)
DESCRIPTION

Mirum is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. The company's approved medication is LIVMARLI (maralixibat) oral solution which is approved in the United States for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. LIVMARLI, an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 clinical trial for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b clinical trial for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC. Mirum was formed in 2018 and is based in Foster City, California.

DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 2 of 2
Type: Add-on Acquisition M&A Deals 2 of 2
State: California M&A 2 of 2
Country: United States M&A 2 of 2
Year: 2025 M&A 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-05-23 Satiogen

Del Mar, California, United States

Satiogen operates as a virtual company by outsourcing all activities required to validate the bile acid brake concept. Its focus has been on preclinical experiments for proof of concept, on collaborating in clinical trials that confirm effects in humans, and on assembling an intellectual property portfolio. Satiogen was formed in 2007 and is based in Del Mar, California.

Buy -
Mergr

Solution for

Product

Company

Legal